February 9, 2018 | Posted by Team in Innovation Highlight, New Innovations |
A three-in-one solution for obtaining 100% accurate amino acid sequences for antibody proteins
Obtaining the sequence of monoclonal antibodies (mAbs) is crucial for the development of some novel biotherapeutics. However, the need to extensively characterize mAbs at the molecular level presents a unique challenge to drug developers and manufacturers. To address this difficulty, Bioinformatics Solutions, Inc. (BSI) has developed the proprietary de novo antibody protein sequencing technology, based on their PEAKS AB Software, to sequence antibodies
This de novo antibody sequencing service is a 3-in-1 solution for obtaining 100% accurate amino acid sequences for antibody proteins with unknown sequences. BSI combines state-of-the-art top-down and bottom-up mass spectrometry (MS) technologies to achieve high accuracy of the constructed sequence with amino acid-level confidence.
Discriminating isoleucine from leucine
The latest EThcD (electron-transfer/higher-energy collision dissociation) fragmentation scheme is incorporated into the bottom-up MS workflow. The rich MS/MS spectra derived from EThcD fragmentation not only improves the accuracy and sensitivity of de novo sequencing but also generates signature w-ion for direct discrimination of the isobaric amino acids, isoleucine, and leucine. In turn, from their bottom-up MS analysis, BSI derives the antibody protein sequences with isoleucine and leucine differentiation by the EThcD method.
Addressing antibody heterogeneity challenges
In addition, the top-down MS workflow focuses on the intact mass of light and heavy chains. This addresses the antibody heterogeneity issues such as C-terminal lysine truncation and glycan forms, which cannot be well answered by bottom-up methods. The top-down MS result can also further validate the bottom-up sequencing result.
By integrating bottom-up MS analysis with EThcD and top-down MS approaches, the de novo antibody sequencing with Ile/Leu differentiation service offered by BSI can guarantee 100% sequence accuracy.
Overall, the industry demands more extensive and accurate characterization of antibodies, and BSI strives to answer this call. With continuous improvement and optimization, BSI sets to provide the most robust next-generation protein sequencing. Learn more.
January 13, 2018 | Posted by Team in Innovation Highlight, New Innovations |
by Gursatya “Guru” Singh, Director of Scientific Content, Science Exchange
In 2017, we zealously scouted for innovative new technologies and external research partners that can help accelerate the speed of your R&D and take your science to market via the fastest path. Once identified, these resources are made accessible, hassle-free, through the Science Exchange Marketplace.
We remain steadfastly dedicated to this pursuit in 2018, so every month you will get a sneak peek of the five innovations from our recent marketplace additions that are worth your attention. Sit back and Take 5! If something grabs your interest, click on the provided link to learn more about each service.
TLA TECHNOLOGY FOR TARGETED NGS OF GENES THAT MATTER
This technology provides complete sequence information of genes, oncogenes in patients, and transgenes, integration sites and gene editing events in (CHO) cell lines and animal models.
By designing a primer pair specific for a locus of interest, TLA enables the amplification and sequencing of > 10,000s of basepairs of surrounding sequence information.
LEARN MORE
VARIANTFIND™ (AKA MULTISITE SATURATION MUTAGENESIS)
This flexible and scalable PCR-based platform can create DNA libraries for any gene of interest.
The platform is not limited by target gene length or %GC composition and all variants are generated by using a targeted mutagenesis approach.
LEARN MORE
COMPLEX 3D DRUG SCREENING
This technology involves patented microplates, in standard 384-well format, but with each well containing 150 individual microwells, in each of which can be grown a different 3D cell culture/spheroid.
This ultra-high-throughput platform improves data consistency and reduces the number of replicate plates required, saving time and money for the investigator.
LEARN MORE
XPLORE-NGS PATHOGEN TESTING SERVICE
This service can identify all the known pathogens including bacteria, viruses, and even fungi simultaneously in a single test using sequencing and genomic analysis approaches.
With genetic sequencing and advanced informatics, Xplore-NGS testing produces faster and more accurate results than culture-based methods and other molecular-based approaches.
LEARN MORE
TISSUE PHANTOM DEVELOPMENT
This technology uses hydrogel formulations to mimic properties of native tissue, such as fat, muscle, and skin. Resulting “phantoms” can be used to test medical devices and surgical tools.
Some of the diverse applications of tissue phantoms include skin substitutes for testing sutures, casts of major organs for surgical training, and arterial models of atherosclerosis and cardiovascular disease.
LEARN MORE
Request quotes for these innovative services today!
December 18, 2017 | Posted by Team in Innovation Highlight, New Innovations |
–Chandreyee Das, Ph.D. | Senior Content Manager, Science Exchange
Bispecific T-Cell Engager Antibodies, or “BiTE” antibodies, are thought to be safe and efficacious candidates for cancer immunotherapy.
But the specificity of membrane receptor binding is hard to characterize.
A unique new technology from Retrogenix has caught the attention of dozens of pharmaceutical companies in the immunooncology space — seeking to use Retrogenix services for discovering immune checkpoint modulators, perform CAR-T cell specificity screening, and more. It’s not surprising that the company was recognized by an award from the Queen of England!
Visit the Retrogenix storefront to connect with their team
In 2006, Fasteris became the first service provider to order an Illumina NGS instrument. This year, they celebrated 20 years of providing NGS services to the world, applying their expertise to diverse studies, ranging from transcriptomics to elucidate T-cell differentiation, microbiome metagenomics, herpes virus infection in wild frogs, and host-pathogen interactions in tortoises.
Earlier this year, the company collaborated on a project to sequence cell-free DNA from over 6,000 cases of fetal aneuploidy — using a novel method developed at Fasteris in 2013.
Start a project today with Fasteris
Gene editing is hard enough — and it’s even harder in primary cells. A company that combines expertise in gene delivery AND gene editing has an advantage in this space — and that company is B-MoGen Biotechnologies, recent recipients of an NIH grant for developing novel genome editing technologies.
B-MoGen offers a proprietary technology for editing nearly any primary human cell type — CD34s, T cells, B cells, etc.
Gain the editing edge with the B-MoGen team
October 26, 2017 | Posted by Team in Innovation Highlight, New Innovations |
Chandreyee Das, Ph.D. | Senior Content Manager, Science Exchange | www.scienceexchange.com
Virtual Reality Software: Explore biology at nanoscale
From “Fantastic Voyage” (1966) to “A Wind in the Door” (1973), fiction has adored the idea of exploring the body at cellular and molecular levels. Now, virtual reality (VR) software, combined with the computational power afforded by blockchain technology, makes such journeys possible.
For your next computer-aided drug discovery/development (CADD) project, especially if you are collaborating with researchers across multiple sites, try molecular visualization using VR technology — now available from Nanome through Science Exchange.
Visit the Nanome storefront to connect with their team!
Cancer Genetics: Connect patients to discoveries
It’s a great day for precision medicine, with the unveiling of the first global directory of patient-derived xenografts (PDX).
Despite the attention given to precision medicine, however, less than 5% of cancer patients are participating in clinical trials. In the discovery phases of R&D, obtaining biospecimens of specific genotypes is also a continuing challenge.
Oncologists on Science Exchange can now accelerate their research with Cancer Genetics, Inc., a global CRO with a history of thought leadership in precision medicine.
Start a project today with Cancer Genetics, Inc.
Stem Cell-based 3D Organoids: Predict Preclinical Efficacy and Toxicity
Organoids, particularly brain organoids, have enabled breakthrough research in Alzheimer’s disease, glioblastoma, and even ZIKA virus-induced microcephaly. By using pluripotent stem cells as a source of the multiple cell types present in an organoid, preclinical researchers can recapitulate in vivo-like tissue architecture and cellular heterogeneity.
Many of these discoveries were made by the founders of 3Dnamics, a new service provider on the Science Exchange network. The 3Dnamics team was built by stem cell pioneers and neuroscientists at Johns Hopkins University School of Medicine. If you are in the process of developing a model system for your preclinical or discovery-phase research, take advantage of 3Dnamics’ expertise.
Visit the 3Dnamics storefront
October 4, 2017 | Posted by Team in Innovation Highlight, New Innovations |
Chandreyee Das, Ph.D. | Senior Content Manager, Science Exchange | www.scienceexchange.com
This installment of New on Science Exchange features spectrometry experts at CMP Scientific, Protypia, CovalX, Nightingale Health, and The Scripps Center for Metabolomics. Ready.. set … analyze.
CMP Scientific: Capillary electrophoresis – mass spectrometry (CE-MS) experts
Analytical researchers frustrated by the long separation times, high sample requirements, or low throughput of LC-MS have long been attracted to the advantages of CE-MS.
In 2015, the CE-MS technique was revolutionized — in that year, Brooklyn, New York-based CMP Scientific pioneered the EMASS-II CE-MS ion source, a novel interface between the capillary and the mass spectrometer’s electrospray emitter that conferred nanoflow sensitivity and high electrospray efficiency.
Since then, CMP Scientific has gained a proven track record for helping drug discovery and development companies develop CE-MS methods for pharmaceutical and biopharmaceutical analysis. Will your research program be the next to benefit from CE-MS technology?
Connect with the CMP Scientific team on Science Exchange.
The Scripps Center for Metabolomics: Respected mass spec core exposes the exposome
What are the biological effects of the exposome — i.e., the sum of all environmental toxicants, food contaminants and supplements, drugs, and antibiotics your body is exposed to daily?
Thanks to XCMS/METLIN, a software combined with a cloud-based database founded by the researchers at the Scripps Center for Mass Spectrometry and Metabolomics, investigations into the elusive exposome are now possible. On September 25, the lab published the results of their initial study — and we were very excited to have such a groundbreaking team join the Science Exchange network!
The facility serves its customers both at Scripps Research Institute as well as in the broader biotechnology community with its analytical expertise, for routine as well as specialty projects. They offer not only ESI, MALDI, and GC/MS of a wide range of samples and analytes, but also access to the world’s leading metabolomics/lipidomics platform.
Nightingale Health: Epidemiology-scale metabolomics, using NMR
Based in Helsinki, Finland, Nightingale Health has been transforming population health studies using its novel, NMR spectroscopy-based platform to detect multiple metabolites, across diverse pathways, in human plasma and serum. This fully automated biomarker quantification method can provide superior repeatability compared to mass spectrometry methods and is coupled with automated quality control.
Now available on Science Exchange, Nightingale Health’s services are accessible to researchers seeking novel biomarkers for large population studies of cardiovascular health, diabetes, and other aspects of metabolic syndrome.
Protypia: Advancing immunooncology through quantitative proteomics
The complexity of immune checkpoint signaling has led the field to the conclusion that there are more determinants to immunotherapeutic efficacy than PD-1 or PD-L1 expression alone. Vanderbilt University’s Daniel Liebler, President and Founder of Protypia, has used his team’s expertise in quantitative proteomics to show that differential glycation of checkpoint signaling proteins could affect tissue staining results as well as signaling protein function [abstract].
Visit the Protypia storefront to request a quote for your proteomics project — this team might just enable your next drug discovery breakthrough.
CovalX: High-Mass MALDI yields cost-effective info on epitopes
Founded in 2005, this global, fast-growing service provider established its prominence by developing a very differentiated technology — fast, sensitive and accurate analysis of protein complexes by High-Mass MALDI mass spectrometry. Unfragmented and undigested, the protein complexes are detected intact using specially developed cross-linking reagents and high-mass detection system.
Combined with CovalX’s covalent crosslinking technology, this mass spectrometry method provides a method for epitope mapping that is faster and more cost-effective than many other conformational analysis techniques. For researchers analyzing protein biotherapeutics and biosimilars, it’s an attractive option.
Browse these and other new service providers on Science Exchange today!
September 20, 2017 | Posted by Team in Innovation Highlight, New Innovations |
by Chandreyee Das, Ph.D., Senior Content Manager, Science Exchange | www.scienceexchange.com
We observe World Heart Day at Science Exchange by highlighting a novel technology for assessing cardiac safety, from the Efimov Lab at George Washington University. Other newcomers on our platform that we present to you are ActiveMotif, Oncodesign, QurAlis, and Worldwide Clinical Trials.
ActiveMotif: Time to RIME (Rapid IP-MS of endogenous proteins)
It’s the 20th anniversary of the discovery of chromatin — and researchers can treat their favorite chromatin samples to ActiveMotif’s RIME service (Rapid immunoprecipitation mass spectrometry of endogenous
RIME service from ActiveMotif includes nuclear isolation, sonication, IP, purification, tryptic digestion, MS, and data analysis
proteins). It is an ideal method for identifying transcriptional cofactors and other associated proteins within multi-protein complexes, and is often performed in parallel with ChIP-seq.
A leading provider of kits and services for studying gene regulation (both genetic and epigenetic), ActiveMotif is no stranger to chromatin. RIME is just one of a comprehensive menu of gene regulation services that ActiveMotif offers through Science Exchange — visit the storefront to browse their capabilities.
QurAlis: Harvard team uses Dead Sea microbes in novel assays
Founded in May 2017 by Clifford Woolf, Professor of Neurology and Neurobiology at Harvard Medical School, Kevin Eggan, Professor of Regenerative Biology at Harvard, Kasper Roet, Harvard Research Fellow, and Q-State Biosciences, QurAlis focuses the power of Q-State’s powerful, 100% optical electrophysiology platform on novel, stem cell-derived, disease-in-dish models of ALS.
It’s a Dead Sea microorganism that is the basis of the enabling Q-State technology. QuasAr proteins, derived from this microbe, respond to action potentials and synaptic signals by emitting near-infrared fluorescence. These Optopatch assays thus deliver higher throughput and information content than traditional patch clamp assays, and they also provide better resolution and lower phototoxicity than other optical screening tools.
We’re very excited to have QurAlis join Q-State Biosciences on our network, giving neurobiology researchers easy access to the expertise of the QurAlis team.
Worldwide Clinical Trials: Early phase services now available on Science Exchange
In the high-stakes service category of clinical trials, Worldwide stands out. In fact, Worldwide’s Chief Medical and Scientific Officer, Michael F. Murphy, M.D., Ph.D., was recently named one of the PharmaVOICE 100 Most Inspiring People of 2017 — for the impact of Dr. Murphy’s dedication to innovation.
Continuously working to improve trial design and patient outcomes, Worldwide now offers early phase services on the Science Exchange network. Click on the Worldwide storefront to access this major global CRO without needing a separate contract.
Efimov Lab: Predictive preclinical models of cardiovascular toxicology
An apt addition to the Science Exchange platform, in time for World Heart Day (September 29!), is the Efimov Laboratory at George Washington University.
Known around the world as a leader in cardiovascular science and biomedical engineering, Dr. Igor Efimov and his team developed a method for optically mapping organotypic cultures of donor human heart slices, enabling users to test the cardiac safety and efficacy of therapeutic candidates.
The culture method preserves heart tissue architecture and extracellular matrix — aspects of heart health that cannot be revealed by iPSC-derived cardiac cells or other traditional assays for cardiovascular toxicology. Visit the lab’s storefront for a list of their recent exciting publications — this is clearly a team to watch.
Oncodesign: Preclinical assessment of anti-cancer therapies
True thought leaders in the field of preclinical drug discovery and development, Oncodesign made the news last year when it partnered with Bristol-Myers Squibb to develop novel macrocyclic candidates and test them using their proprietary xenograft models and imaging technology.
Now, Oncodesign’s services are easily accessible to Science Exchange requesters. We get extremely excited thinking that a requester on our platform with a promising therapeutic candidate may now use Oncodesign’s Predict®, Chi-mice®, Pharmimage® and other platforms to characterize their candidate, speeding it along the path to potential cancer patients. Start a conversation with this leading CRO by submitting your Scope of Work here.
Connect with a new provider today!
Are you new to Science Exchange? See how it works.
August 22, 2017 | Posted by Team in Innovation Highlight, New Innovations |
Nobel-worthy nanosensors
In 2007, Charles Lieber, the Harvard scientist who many say is in the running for a Nobel prize, co-founded Vista NanoBioSciences to enable drug discovery researchers to use his team’s nanosensor technologies for label-free, ultrasensitive detection of proteins, nucleic acids, and even single viral particles.
Vista NanoBioSciences’ ultrasensitive biomarker detection platform (left) uses functionalized nanowires (“NW”) that respond to interactions with individual biomolecules.
Now available through Science Exchange, Vista NanoBioSciences offers biomarker assays using its portable NanoBioSensor™ and BioTracker™ platforms. Vista’s NanoBioSensor precisely detects and measures biomarkers in a finger-stick drop of blood, other bodily fluid, or tissue culture – without labeling and in less than 10 minutes. Vista’s BioTracker provides continuous monitoring of dynamic changes in the targeted analytes of any biological material. Both devices are portable, exhibiting very high sensitivity (10³ increase over ELISA), high specificity, across multiple logs of concentration, in real time.
Taking the pain out of protein purification with MacroDSF
Empowered by high-throughput protein purification and structure determination technologies, structure-based drug discovery is enjoying a resurgence.
NovAliX, a new provider on the Science Exchange network, gives you access to the ProteoPlex MacroDSF platform, an exciting tool for rapidly optimizing conditions for protein purification and crystallization.
The instrument quickly optimizes protein concentration, pH value, salt, buffer, stabilizing additive, etc — potentially increasing a purified protein’s stability or even the resolution of its crystal structure!
NovAliX also offers a broad range of biophysical characterization services to provide a complete picture of the protein of interest.
Fluidigm custom assay development
Interested in Fluidigm’s powerful mass cytometry and microfluidics platforms, but lack the resources to design the perfect assay?
Now you can take advantage of Fluidigm’s expertise using the company’s own team of assay development scientists. Through Science Exchange, you can order custom assays for Fluidigm’s CyTOF®, Helios®, and integrated fluidic circuit-based platforms.
Oncology, from ABL1 to ZAP70
Based in Freiburg, Germany, ProQinase has been supporting oncology research for 16 years. Now on Science Exchange, ProQinase offers biochemical assay services (such as kinase screens), cellular assay services (such as proliferation, invasion and spheroid assays), and in vivo assay services (including immuno-oncology and metastasis models).
The scientific staff at ProQinase are thought leaders in oncology research. At the 2017 AACR Annual Meeting, they presented a novel assay platform to distinguish ATP-competitive from non-ATP-competitive kinase inhibitors.
Medicinal chemistry and process optimization
If you’re looking for a full-service laboratory to execute your chemistry projects, you’ll be happy to see the addition of Kalexsyn, a chemical synthesis powerhouse based in Michigan, U.S.A, to the Science Exchange network.
Whether it’s developing novel scaffolds, SAR, modification of complex natural products or challenging macrocyclic peptides, Kalexsyn’s deep bench of Ph.D. chemists provides IP-enabling expertise.
The Kalexsyn team has produced over 1000 publications and patents and has served over 85 pharmaceutical and biotechnology companies.
Connect with a new provider today!
Are you new to Science Exchange? See how it works.
August 2, 2017 | Posted by Team in Innovation Highlight, New Innovations |
Image of Colon Tumor Stem Cells courtesy of OcellO
If you aren’t exploring the latest cell culture models of human tissue for nonclinical and preclinical testing, you should be.
That’s the bottom line of today’s Science Exchange service provider roundup — three of the five newest service providers on our platform are experts in developing predictive models.
Advances in predictive model systems
Axiogenesis, based in Germany, develops iPSC-derived models of cardiac tissue, neurons, and other cell types. In late 2016, the company made the news when researchers at the United States FDA published a peer-reviewed study showing that Axiogenesis’s Cor.4U cardiomyocyte model was the most predictive model in cardiac safety tests. Last month, researchers at Wake Forest University used the Cor.4U model to develop a digitally trackable beating-heart biosensor. The future of cardiac safety clearly lies beyond hERG channel electrophysiology!
Generating tissue models with precise spatial resolution is possible using 3D bioprinting, in which Cypre Biotech is an expert. Based in San Francisco, USA, the company focuses on customizing the extracellular matrix of tumor microenvironment models to match certain cancer subtypes. Given the impact of new cancer drugs, including certain immunotherapies, on the tumor microenvironment, technologies such as that developed by Cypre are going to be needed for testing safety and efficacy.
The third service provider in this roundup excelling in the development of clinically relevant microtissue models is OcellO, headquartered in the Netherlands. Researchers at OcellO have published numerous peer-reviewed studies showing how combining three-dimensional tissue culture with high-throughput imaging can enable efficient, automated screening and phenotypic profiling. Their most recent publication showed that phenotypic screening of kinase inhibitors could reveal potential new targets for polycystic kidney disease (view abstract in the Resources section of the OcellO storefront).
Analytical methods for translational research
As model systems advance in complexity and throughput, analytical methods must keep pace. Two service providers new on Science Exchange are known for their expertise in developing reliable analytical methods.
Pangaea Oncology is one of the most prestigious laboratories in the world in the fields of molecular diagnostics, pathology, and related analysis services for translational research. We are thrilled to have the Pangaea team, led by expert Dr. Rafael Rosell and Nobel laureate Dr. Santiago Ramón y Cajal, join the Science Exchange platform! Pangaea Oncology was the first laboratory in Spain to be accredited to perform certain genetic tests for cancer in serum/plasma samples, advancing precision medicine.
We also bring you Metis Laboratories, whose analytical expertise centers on radiotracer-based assays. These assays remain one of the most sensitive and specific platforms for assessing ligand binding and compound distribution; however, complex handling requirements mean that outsourcing these studies is far more practical than developing radiotracer assays in house.
Connect with a new provider today!
Are you new to Science Exchange? See how it works.
April 7, 2017 | Posted by Diana Truong in Events, Innovation Highlight, New Innovations |
Greetings from the AACR Annual Meeting!
This year, we heard Joe Biden’s report on the progress of the Beau Biden Cancer Moonshot Initiative, compared immuno-oncology combination therapies, and mulled over the use of CRISPR screening to finding epigenetically controlled loci.
Joe Biden delivers the Cancer Moonshot Initiative update at AACR 2017
We also checked out the groundbreaking research being done by service providers on the Science Exchange network. Their work directly addresses the recommendations made last fall by the Moonshot’s Blue Ribbon Panel, and we are excited to give cancer researchers rapid access to these technologies through the Science Exchange platform!
Here are a few highlights from our exploration of #AACR17:
First humanized mouse model of tumor growth in bone: Pharmatest and Taconic Biosciences
The Moonshot Initiative’s recommendations specifically called out the potential of humanized mouse models to recapitulate the cellular architecture and heterogeneity found in human tumors. Traditional preclinical models that lack functional interactions between tumor, immune system and microenvironment have not been effective at predicting safety and efficacy of immunomodulating cancer drugs.
Taconic Biosciences showcases its novel animal models at AACR 2017
Pharmatest Services, Ltd. and Taconic Biosciences, both leaders in the development of predictive animal models, presented a poster at AACR 2017 showing the proliferation of human breast cancer cells in the bone injection site of humanized mice. The observed tumor growth, bone remodeling, and infiltration by human immune cells were similar to that seen in human breast cancer patients suffering from bone metastases.
Validation of this mouse model would be a very promising development for preclinical testing of immuno-oncology drug candidates and combination therapies.
Mass spectrometry imaging to characterize tumor microenvironment: Imabiotech
Imabiotech’s novel mass spectrometry imaging technology provides better toxicity and efficacy assessments in a number of therapeutic research areas, including immuno-oncology.
One challenge facing the Cancer Moonshot Initiative is that novel technologies are required to address tumor heterogeneity (at the cellular and molecular levels). Thus, the Blue Ribbon Panel called out multiplexed, quantitative imaging as a promising way to connect function with localization.
Imabiotech Corporation is a widely-published expert in the emerging field of mass spectrometry imaging, which is a promising technology to address tumor heterogeneity. Their poster and exhibit at AACR 2017 showcased how mass spectrometry imaging could be used to quantitatively characterize responses to immunotherapy in the tumor microenvironment, with spatial resolution.
Toward 3D patient-derived models of breast cancer, lung cancer, and glioblastoma: KIYATEC, Inc.
Another of the most challenging aspects of oncology is the fact that each patient has a different response to a particular therapy. Recognizing this, the Moonshot Initiative’s recommendations included a call to establish patient-derived test models, such as organoids and xenografts, in which candidate drugs could be tested before treatment.
KIYATEC presents 3D cell-based models for drug response profiling at AACR 2017
KIYATEC, whose expertise lies in generating and using 3D cell-based models for drug response profiling, presented their work on breast cancer, lung cancer, and glioblastoma multiforme (GBM), in three posters at AACR 2017.
One study addressed the challenges facing small cell lung cancer (SCLC) patients, for whom surgical resection is rarely feasible. Therefore, patient-derived tissue is difficult to obtain. KIYATEC was able to isolate functional cancer stem cells and circulating tumor cells, label-free, from SCLC patients, with the aim of developing 3D microtumors from these cells.
KIYATEC also showed that 3D models of breast cancer, which incorporated multiple stromal cell types and immune cells, responded differently to immune checkpoint inhibitors than standard 2D cell culture models. Finally, KIYATEC tackled GBM, for which therapy is particularly confounded by intra-tumor and inter-patient heterogeneity. They developed an efficient method to develop patient-derived 3D models, which may enable more personalized treatments for GBM.
Interested in working with these service providers? Order services on Science Exchange today, or contact us about your project.
October 29, 2013 | Posted by Brianne Villano in New Innovations |
Some companies skirt regulations, opting instead to go off the radar. American CryoStem‘s Anthony Dudzinski‘s first words to me on the phone during our discussion were, “We follow the rules.” They’ve accumulated the greatest depth of adipose tissue-based cellular technology research relative to creating their laboratory and processes at a clinical cGMP level, and they’ve done it by actively engaging FDA consultants in the process.
Anthony F. Dudzinski, COO at American CryoStem
They’re looking at adipose-derived stem cells – also known as mesenchymal cells. ‘Mesenchymal’ was the original name of cells that came from bone marrow, and the two types are 98-99% identical, but there are some difference with the protein markers and capabilities of adipose vs. marrow cells.
Marrow cells are better for blood-borne diseases like lymphomas, whereas adipose-derived stem cells seems to be much more effective than marrow for structural issues. The concentration of adipose cells per gram of source material is actually 500-1000x greater than bone marrow from same patient. They have the ability to differentiate into a multitude of other cells including chondrocytes. This has incredible potential for how doctors treat sports injuries and aging issues.
Anthony set the stage for the importance of the research,”Most sports or age injuries are due to ligament or cartilage damage to the extent that most of them are bone on bone. So what if we could take Mrs. Smith who’s 55 and played tennis most of her life but can’t play anymore and doesn’t want to have knee replacement surgery. We can take cells out of the fat in her own body, attach them to a scaffold to induce chondrocytes, insert them into the meniscal cartilage area, and as time goes by with normal rehabilitation, her body regrows cartilage in her knees and her pain is gone.”
Anthony is excited about the implications for creating tissue for repairs, wound healing, burns, tendon injury, etc., all coming out of cells taken from adipose tissue. Read the rest of this entry »
Follow Us